Ultragenyx

Yahoo Finance • 20 hours ago

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today repo... Full story

Yahoo Finance • 2 days ago

Assenagon Boosts Ultragenyx Pharmaceutical Inc. (RARE) Stake by 439% Amid Breakthrough Pipeline

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is among the most promising biotech stocks to buy according to hedge funds. According to a recent disclosure with the SEC, Assenagon Asset Management S.A. lifted its holdings in Ultragenyx Pharm... Full story

Yahoo Finance • 4 days ago

Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President

NOVATO, Calif., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced the appointment of Eric Olson as chief business officer (CBO) and executive vice president effective September 22, 2025, fo... Full story

Yahoo Finance • 8 days ago

Regeneron nabs FDA label expansion for Ultragenyx-partnered cholesterol drug

[FDA Approved Products or Drugs] Olivier Le Moal Regeneron Pharmaceuticals (NASDAQ:REGN [https://seekingalpha.com/symbol/REGN]) announced on Friday that the U.S. FDA approved a label expansion for its anti-cholesterol agent Evkeeza, marke... Full story

Yahoo Finance • 18 days ago

Is Ultragenyx Pharmaceutical (RARE) a Compelling Long-Term Opportunity?

Sands Capital, an investment management company, released its “Sands Capital Select Growth Strategy” Q2 2025 investor letter. A copy of the letter can be downloaded here.  U.S. large-cap growth equities recovered from a sharp sell-off in e... Full story

Yahoo Finance • 26 days ago

Ultragenyx releases long-term phase 3 data on gene therapy for metabolic disorder

[Rare disease. health problem. woman doctor showing words written on a tablet.] * Ultragenyx Pharmaceutical (NASDAQ:RARE [https://seekingalpha.com/symbol/RARE]) said that week 96 phase 3 data of its gene therapy DTX401 for glycogen stor... Full story

Yahoo Finance • 26 days ago

Ultragenyx Announces Positive Longer-term Data from Phase 3 Study of DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)

At Week 96 participants experienced even greater reductions in daily cornstarch intake while maintaining low levels of hypoglycemia, improved levels of euglycemia and improved fasting tolerance Phase 3 results are further supported by ear... Full story

Yahoo Finance • last month

Ultragenyx to Participate at Investor Conferences in September

NOVATO, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic dise... Full story

Yahoo Finance • last month

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

NEW YORK, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE).  Such investors are advised to contact Danielle Pe... Full story

Yahoo Finance • last month

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE).  Such investors are advised to contact Danielle Pe... Full story

Yahoo Finance • 2 months ago

Ultragenyx earnings beat by $0.13, revenue topped estimates

Investing.com - Ultragenyx (NASDAQ: RARE) reported second quarter EPS of $-1.17, $0.13 better than the analyst estimate of $-1.30. Revenue for the quarter came in at $166.5M versus the consensus estimate of $161.97M. Ultragenyx’s stock... Full story

Yahoo Finance • 2 months ago

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) Reports Mixed Q2 2025 Earnings, Beats Revenue Estimates and Narrows Loss

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE [https://www.chartmill.com/stock/quote/RARE/profile]) reported its second-quarter 2025 financial results, delivering mixed performance relative to analyst expectations. The company’s revenue and e... Full story

Yahoo Finance • 2 months ago

Ultragenyx Reports Second Quarter 2025 Financial Results and Corporate Update

Second quarter total revenue of $166 million, Crysvita® revenue of $120 million and Dojolvi® revenue of $23 million Reaffirm 2025 Revenue Guidance: Total revenue between $640 million to $670 million, Crysvita revenue of $460 million to $4... Full story

Yahoo Finance • 2 months ago

Ultragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate Update

NOVATO, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic disea... Full story

Yahoo Finance • 3 months ago

Ultragenyx's SWOT analysis: rare disease biotech stock faces pivotal trials

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biotechnology company focused on developing novel therapies for rare and ultra-rare diseases, stands at a critical juncture in its journey. With several key clinical trials underway and a di... Full story

Yahoo Finance • 3 months ago

Bank of America Securities Reiterated a Buy Rating on Ultragenyx Pharmaceutical (RARE)

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the Best 52-Week Low Stocks to Buy According to Analysts. On July 14, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on Ultragenyx Pharmaceutical Inc. (NASDAQ:RAR... Full story

Yahoo Finance • 3 months ago

Ultragenyx Pharmaceutical Enters Oversold Territory (RARE)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the R... Full story

Yahoo Finance • 3 months ago

Health Canada extends Evkeeza approval to treat HoFH in infants

TORONTO - Health Canada has approved Ultragenyx Pharmaceutical Inc.’s (NASDAQ:RARE) Evkeeza (evinacumab) for children as young as 6 months old with homozygous familial hypercholesterolemia (HoFH), the company announced Monday. The announce... Full story

Yahoo Finance • 3 months ago

Ultragenyx (RARE) Falls 26% as New Treatment Fails to Get FDA Green Light

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the stocks drowned heavily. Are you holding any? Ultragenyx fell by 26.05 percent week-on-week as investor sentiment was largely dragged down by the Food and Drug Administration’s (FD... Full story

Yahoo Finance • 3 months ago

Ultragenyx gets Complete Response Letter for Sanfilippo syndrome gene therapy

[Paper with words Sanfilippo syndrome and glasses.] * The U.S. FDA has issued a Complete Response Letter to Ultragenyx Pharmaceutical (NASDAQ:RARE [https://seekingalpha.com/symbol/RARE]) for its BLA for UX111 (ABO-102), its AAV gene the... Full story